Literature DB >> 19725996

Recurrent APC gene mutations in Polish FAP families.

Andrzej Pławski1, Marta Podralska, Ryszard Słomski.   

Abstract

The molecular diagnostics of genetically conditioned disorders is based on the identification of the mutations in the predisposing genes. Hereditary cancer disorders of the gastrointestinal tracts are caused by mutations of the tumour suppressor genes or the DNA repair genes. Occurrence of recurrent mutation allows improvement of molecular diagnostics. The mutation spectrum in the genes causing hereditary forms of colorectal cancers in the Polish population was previously described. In the present work an estimation of the frequency of the recurrent mutations of the APC gene was performed. Eight types of mutations occurred in 19.4% of our FAP families and these constitute 43% of all Polish diagnosed families.

Entities:  

Year:  2007        PMID: 19725996      PMCID: PMC2736979          DOI: 10.1186/1897-4287-5-4-195

Source DB:  PubMed          Journal:  Hered Cancer Clin Pract        ISSN: 1731-2302            Impact factor:   2.857


Introduction

Molecular diagnostics of cancer predisposition is very important for the medical treatment of the patient and persons belonging to the high risk group. Molecular studies enable the detection of mutation carriers and release from unreasonable stress of persons from the group with increased risk of cancer occurrence. The mutation spectrums in the genes predisposing to colorectal cancer in the Polish population have been described [1-4]. In the present work we focused on recurrent mutations of the APC gene causing FAP [5]. Familial adenomatous polyposis (FAP) is characterized by the appearance of numerous polyps in the large intestine. Untreated polyps lead to the development of colorectal cancer before age of 50 years. FAP is a genetically determined disorder, inherited in an autosomal dominant manner. The correlation between mutations of the APC gene and the occurrence of familial adenomatous polyposis was described in 1991 [1,2] and since then, mutations of the APC gene have been investigated in research centres leading to identification of various mutation types. APC gene mutations arise de novo in 1 per 10,000 newborns. The APC gene is localized on chromosome 5q21 and consists of 21 exons. Mutations of the APC gene, in most cases, are small deletions or insertions with the most frequent mutations, in the greater part of the described populations, being the AAAGA deletion at codon 1309 and the ACAAA deletion at codon 1061.

Patients

Clinical diagnoses of FAP patients were conducted in collaborating genetic centres or gastroenterology clinics in the place of residence of patients. So far, samples of DNA belonging to 280 Polish FAP families have been collected in the DNA bank of Polish FAP families established in 1997 at the Institute of Human Genetics, Polish Academy of Science in Poznan.

Molecular methods

DNA was extracted from peripheral blood cells by the classical phenol purification method and entire coding sequence of APC gene was screened for mutations by PCR-HD and SSCP methods in 280 probands. DNA fragments showing heteroduplex or additional pattern in SSCP analysis were sequenced by direct PCR product sequencing and analyzed using a MegaBace 500 sequencer according to the manufacturer's specifications.

Results and discussion

We identified 72 mutations in 124 of our 280 FAP families and observed eight types of recurrent mutations. The mutations and age of onset are presented in Table 1. Two of them were localized in exon 11 and the remaining six in the 3' part of exon 15. The most frequent mutation, 3927–3931delAAAGA, occurred in twenty-eight families (10%); the second one was 3183–3187delACAAA, occurring in eight families (2.8%); and the third most frequent mutation was 3202–3205delTCAA, detected in 5 families (1.7%). In our FAP patients Y500X occurred in four families (1.4%) while Q978X was detected in three families. Each of the remaining four types of mutation occurred in two families and the frequencies of these mutations were below one percent.
Table 1

Fifty-four recurrent mutations identified in APC gene and age of onset in a group of 124 diagnosed Polish FAP families

No.FamilyClinical manifestationMutationExonAge of onset
1.9001FAP1490–1491insT1135

2.9129FAP1490–1491insT1110

3.9117FAP1500T>A11ND

4.9141FAP1500T>A11ND

5.9158FAP1500T>A11ND

6.9182FAP1500T>A11ND

7.9031FAP2626subC>T15ND

8.9043FAP2626subC>T1530

9.9099FAP2932C>T15ND

10.9139FAP2932C>T15ND

11.9152FAP2932C>T15ND

12.9028FAP3183–3187delACAAA1528

13.9067FAP3183–3187delACAAA1519

14.9093FAP3183–3187delACAAA1517

15.9108FAP3183–3187delACAAA15ND

16.9111FAP3183–3187delACAAA15ND

17.9192FAP3183–3187delACAAA15ND

18.9262FAP3183–3187delACAAA1524

19.9311FAP3183–3187delACAAA15ND

20.9088FAP3202–3205delTCAA1530

21.9106FAP3202–3205delTCAA1526

22.9213FAP3202–3205delTCAA1528

23.9226FAP3202–3205delTCAA15ND

24.9342FAP3202–3205delTCAA1512

25.9016FAP3927–3931delAAAGA1520

26.9032FAP3927–3931delAAAGA15ND

27.9036FAP3927–3931delAAAGA1513

28.9059FAP3927–3931delAAAGA1518

29.9065FAP3927–3931delAAAGA1536

30.9069FAP3927–3931delAAAGA15ND

31.9071FAP3927–3931delAAAGA1536

32.9075FAP3927–3931delAAAGA15ND

33.9084FAP3927–3931delAAAGA15ND

34.9103FAP3927–3931delAAAGA1526

35.9104FAP3927–3931delAAAGA15ND

36.9105FAP3927–3931delAAAGA1520

37.9118FAP3927–3931delAAAGA15ND

38.9142FAP3927–3931delAAAGA15ND

39.9147FAP3927–3931delAAAGA1529

40.9149FAP3927–3931delAAAGA1516

41.9162FAP3927–3931delAAAGA15ND

42.9187FAP3927–3931delAAAGA15ND

43.9193FAP3927–3931delAAAGA15ND

44.9229FAP3927–3931delAAAGA1522

45.9235FAP3927–3931delAAAGA15ND

46.9237FAP3927–3931delAAAGA1521

47.9244FAP3927–3931delAAAGA1516

48.9292FAP3927–3931delAAAGA1519

49.9300FAP3927–3931delAAAGA1517

50.9312FAP3927–3931delAAAGA15ND

51.9321FAP3927–3931delAAAGA1531

52.9324FAP3927–3931delAAAGA15ND

53.9070Gardner syndrome4129–4130delGT15ND

54.9119FAP4129–4130delGT15ND

ND – no data available

Fifty-four recurrent mutations identified in APC gene and age of onset in a group of 124 diagnosed Polish FAP families ND – no data available In the Human Mutations Database at the Institute of Medical Genetics in Cardiff , considered the most representative population in the world, seven hundred mutations are listed for the APC gene. The most important mutation of the APC gene is 3927–3931delAAAGA. The frequency of these mutations varies depending on populations. The mutation reports describe the frequency of this mutation from 0% in northwest Spain, 2.4% in the Australian population, 5% in Dutch, 7% in Israeli to 16% in the group of Italian FAP patients [6-9]. The second most frequent mutation, 3183–3187delACAAA, is reported with frequency ranging from 0% in northwest Spain, 1.5% in Israeli populations to 8.4% in Australia [6-9]. A study of over 100 Dutch families revealed equal frequency of those two most frequent mutations (3927–3931delAAAGA and 3183–3187delACAAA) [10]. The largest studies of APC gene mutations were performed on a German population [11,12]. The latest published report in 2005 involved the analysis of over 1000 patients. In comparison to this study, the representative study of mutation frequency in the neighbouring population indicated two times higher frequency of 3927–3931delAAAGA, whereas a difference in frequency of 3183–3187del-ACAAA was not observed (Germany 3.8%, Poland 2.7%). The frequency of 3202–3205delTCAA was equal (1.7%) in both populations. In worldwide comparison differences in the frequency of mutations were observed. The Polish population of FAP patients belongs to the group where 3927–3931delAAAGA occurred with higher frequency, whereas the frequency of mutation 3183–3187del-ACAAA occurred with medium frequency in comparison with other populations. The two recurrent mutations localized on exon 11 were observed only in the Polish population. In our two unrelated families with 1490–1491insT brain tumours were observed. Additionally in one family desmoid tumours occurred [10,13]. Another mutation (Q978X) did not occur with higher frequency as described for other populations [14]. In our FAP patient group Q283X, which occurs with frequency of 4.5% in UK FAP patients, was not observed [13]. Recurrent mutations occurred in 54 Polish FAP families. Screening for these mutations permitted us to diagnose 19% of all families in our population but eight types of mutations constitute 43.5% of all our diagnosed families. The mutation study in our population should involve these eight mutations to improve molecular diagnostics of the APC gene. The study was financed by grant 2P05A10728 from the Ministry of Science and Higher Education.
  14 in total

1.  Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland and the Baltic States.

Authors:  G Kurzawski; J Suchy; J Kładny; K Safranow; A Jakubowska; P Elsakov; V Kucinskas; J Gardovski; A Irmejs; H Sibul; T Huzarski; T Byrski; T Debniak; C Cybulski; J Gronwald; O Oszurek; J Clark; S Góźdź; S Niepsuj; R Słomski; A Pławski; A Łacka-Wojciechowska; A Rozmiarek; Ł Fiszer-Maliszewska; M Bebenek; D Sorokin; M Stawicka; D Godlewski; P Richter; I Brozek; B Wysocka; A Jawień; Z Banaszkiewicz; J Kowalczyk; D Czudowska; P E Goretzki; G Moeslein; J Lubiński
Journal:  J Med Genet       Date:  2002-10       Impact factor: 6.318

2.  Mutation analysis of the adenomatous polyposis coli (APC) gene in northwest Spanish patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer.

Authors:  C Ruiz-Ponte; A Vega; A Carracedo; F Barros
Journal:  Hum Mutat       Date:  2001-10       Impact factor: 4.878

3.  Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families.

Authors:  W Friedl; R Caspari; M Sengteller; S Uhlhaas; C Lamberti; M Jungck; M Kadmon; M Wolf; J Fahnenstich; J Gebert; G Möslein; E Mangold; P Propping
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study).

Authors:  G Kurzawski; J Suchy; M Lener; E Kłujszo-Grabowska; J Kładny; K Safranow; K Jakubowska; A Jakubowska; T Huzarski; T Byrski; T Debniak; C Cybulski; J Gronwald; O Oszurek; D Oszutowska; E Kowalska; S Góźdź; S Niepsuj; R Słomski; A Pławski; A Łacka-Wojciechowska; A Rozmiarek; Ł Fiszer-Maliszewska; M Bebenek; D Sorokin; M M Sasiadek; A Stembalska; Z Grzebieniak; E Kilar; M Stawicka; D Godlewski; P Richter; I Brozek; B Wysocka; J Limon; A Jawień; Z Banaszkiewicz; H Janiszewska; J Kowalczyk; D Czudowska; R J Scott; J Lubiński
Journal:  Clin Genet       Date:  2006-01       Impact factor: 4.438

5.  Molecular analysis of the APC gene in 105 Dutch kindreds with familial adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and southern analysis.

Authors:  R B van der Luijt; P M Khan; H F Vasen; C M Tops; I S van Leeuwen-Cornelisse; J T Wijnen; H M van der Klift; R J Plug; G Griffioen; R Fodde
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

6.  Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations.

Authors:  J Björk; H Akerbrant; L Iselius; A Bergman; Y Engwall; J Wahlström; T Martinsson; M Nordling; R Hultcrantz
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

7.  Familial adenomatous polyposis: experience from a study of 1164 unrelated german polyposis patients.

Authors:  Waltraut Friedl; Stefan Aretz
Journal:  Hered Cancer Clin Pract       Date:  2005-09-15       Impact factor: 2.857

8.  Novel germline mutations in the adenomatous polyposis coli gene in Polish families with familial adenomatous polyposis.

Authors:  A Plawski; J Lubiński; T Banasiewicz; J Paszkowski; D Lipinski; A Strembalska; G Kurzawski; T Byrski; S Zajaczek; D Hodorowicz-Zaniewska; T Gach; I Brozek; D Nowakowska; E Czkwaniec; P Krokowicz; M Drews; J Zeyland; W Juzwa; R Słomski
Journal:  J Med Genet       Date:  2004-01       Impact factor: 6.318

9.  Identification and characterization of the familial adenomatous polyposis coli gene.

Authors:  J Groden; A Thliveris; W Samowitz; M Carlson; L Gelbert; H Albertsen; G Joslyn; J Stevens; L Spirio; M Robertson
Journal:  Cell       Date:  1991-08-09       Impact factor: 41.582

10.  MYH Gene Status in Polish FAP Patients without APC Gene Mutations.

Authors:  Marzena Skrzypczak; Marta Podralska; Wolfram Heinritz; Ursula G Froster; Daniel Lipiński; Ryszard Słomski; Andrzej Pławski
Journal:  Hered Cancer Clin Pract       Date:  2006-01-15       Impact factor: 2.857

View more
  5 in total

1.  Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients.

Authors:  Dagmara Dymerska; Pablo Serrano-Fernández; Janina Suchy; Andrzej Pławski; Ryszard Słomski; Krzysztof Kaklewski; Rodney J Scott; Jacek Gronwald; Józef Kładny; Tomasz Byrski; Tomasz Huzarski; Jan Lubiński; Grzegorz Kurzawski
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

2.  APC gene mutations causing familial adenomatous polyposis in Polish patients.

Authors:  Andrzej Plawski; Ryszard Slomski
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

3.  Colorectal cancer in the course of familial adenomatous polyposis syndrome ("de novo" pathogenic mutation of APC gene): case report, review of the literature and genetic commentary.

Authors:  Rafał Stec; Andrzej Pławski; Agnieszka Synowiec; Michał Mączewski; Cezary Szczylik
Journal:  Arch Med Sci       Date:  2010-04-30       Impact factor: 3.318

4.  Comparative‑high resolution melting: a novel method of simultaneous screening for small mutations and copy number variations.

Authors:  Pawel Borun; Lukasz Kubaszewski; Tomasz Banasiewicz; Jaroslaw Walkowiak; Marzena Skrzypczak-Zielinska; Marta Kaczmarek-Rys; Andrzej Plawski
Journal:  Hum Genet       Date:  2014-05       Impact factor: 4.132

5.  Familial adenomatous polyposis of the colon.

Authors:  Andrzej Plawski; Tomasz Banasiewicz; Pawel Borun; Lukasz Kubaszewski; Piotr Krokowicz; Marzena Skrzypczak-Zielinska; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2013-10-22       Impact factor: 2.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.